Raw material experts Dr. David Wellis and Dr. Robert Tressler want to share their knowledge on how to select and source cellular starting materials that build the foundations of successful cell therapies. Dr. Wellis and Dr. Tressler are life sciences experts; both boast decades of experience at the forefront of biomedical research and technology. Mere […]
Next-level donor immune cell characterization can be used as a foundation for promoting high patient response rates. Last week in Part 1 of our donor characterization series, we dove into T cell function and donor immune cell characterization, and how those factors affect how well a patient may respond to immunotherapy. In Part 2 of […]
Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cell therapies are some of the most promising cancer treatments developed in recent years to help fight aggressive cancers. […]
Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its role in regulating T cell activity. PD-1 and its analogs are often called “checkpoint inhibitors” because they act as a checkpoint to […]
T cell immunotherapy is a promising and relatively new field of medicine focused on tailoring a person’s own immune cells to fight disease more effectively. The field has enjoyed early success in the area of cancer immunotherapy, most notably the development of chimeric antigen receptor (CAR) T cells designed to express antigens that specifically target […]